Ionis Pharmaceuticals (IONS) PT Raised to $75 at BMO Capital on Expanded Biogen Deal
Tweet Send to a Friend
BMO Capital raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $75.00 (from $70.00) while maintaining a Outperform rating.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
